The estimated Net Worth of Greg Bradley is at least $2.9 Tausend dollars as of 26 April 2023. Greg Bradley owns over 6,050 units of Petros Pharmaceuticals stock worth over $2,902 and over the last 4 years Greg sold PTPI stock worth over $0.
Sign up
Greg Bradley PTPI stock SEC Form 4 insiders trading
Greg has made over 2 trades of the Petros Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Greg exercised 6,050 units of PTPI stock worth $2,112 on 26 April 2023.
The largest trade Greg's ever made was exercising 6,050 units of Petros Pharmaceuticals stock on 26 April 2023 worth over $2,112. On average, Greg trades about 1,188 units every 14 days since 2021. As of 26 April 2023 Greg still owns at least 8,314 units of Petros Pharmaceuticals stock.
You can see the complete history of Greg Bradley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Greg Bradley's mailing address?
Greg's mailing address filed with the SEC is C/O PETROS PHARMACEUTICALS, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036.
Insiders trading at Petros Pharmaceuticals
Over the last 4 years, insiders at Petros Pharmaceuticals have traded over $0 worth of Petros Pharmaceuticals stock and bought 2,307,580 units worth $4,858,309 . The most active insiders traders include John Djcp Iii Sm Aiv, L.P.M..., Bruce Bernstein und Joshua Silverman. On average, Petros Pharmaceuticals executives and independent directors trade stock every 50 days with the average trade being worth of $74,319. The most recent stock trade was executed by Greg Bradley on 26 April 2023, trading 6,050 units of PTPI stock currently worth $2,112.
What does Petros Pharmaceuticals do?
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
What does Petros Pharmaceuticals's logo look like?
Complete history of Greg Bradley stock trades at Petros Pharmaceuticals
Petros Pharmaceuticals executives and stock owners
Petros Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Fady Boctor M.B.A.,
Pres & Chief Commercial Officer -
Mitchell S. Arnold M.B.A.,
VP of Fin. & Chief Accounting Officer -
Andrew Gesek M.B.A.,
Pres of Timm Medical Technologies -
Robert Weinstein,
Interim Chief Financial Officer -
Keith F. Lavan,
Advisor -
John D. Shulman,
Exec. Chairman -
Mitchell Arnold,
See Remarks -
Fady Boctor,
See Remarks -
Joshua Silverman,
Director -
Keith Lavan,
Chief Financial Officer -
Therapeutics, Llc Metuchen,
10% owner -
John Djcp Iii Sm Aiv, L.P.M...,
-
Andrew Gesek,
President, Timm Medical -
Wayne Remell Walker,
Director -
John D Shulman,
Director -
Bruce Bernstein,
Director -
Greg Bradley,
Director